KSQ
Therapeutics is a biotechnology company that develops genome-based therapeutics for the treatment of cancer and autoimmune diseases... Read moreKSQ
Therapeutics is a biotechnology company that develops genome-based therapeutics for the treatment of cancer and autoimmune diseases... Read more
News
Apr 09, 2025
GlobalNewswire
Press Release: KSQ : KSQ Therapeutics Announces First Patient Dosed in Phase 1/2 Study for KSQ-004EX, a CRISPR/Cas9-Engineered Tumor Infiltrating Lymphocyte (eTIL) Therapy
Sep 24, 2024
GlobalNewswire
Press Release: KSQ : KSQ Therapeutics Announces FDA Clearance of IND Application for KSQ-004EX, a CRISPR/Cas9 Engineered Tumor-Infiltrating Lymphocyte (eTIL) Therapy
Aug 28, 2024
GlobeNewswire
Press Release: KSQ : KSQ Therapeutics to Participate in Upcoming Investor Conferences
Jun 12, 2024
GlobalNewswire
Press Release: KSQ : KSQ Therapeutics Announces First Patient Dosed in Clinical Development Program for KSQ-001EX, a CRISPR/Cas9 Engineered Tumor Infiltrating Lymphocyte (eTIL) Therapy
Nov 29, 2023
BioSpace
KSQ: KSQ Therapeutics Announces FDA Clearance of IND Application for KSQ-001EX, a CRISPR/Cas9 Engineered Tumor Infiltrating Lymphocyte (eTIL) Therapy
Sep 06, 2023
Benzinga
KSQ: KSQ Therapeutics and CTMC Announce Strategic Collaboration to Accelerate the Development of Novel Engineered Tumor Infiltrating Lymphocyte (eTIL) Therapies for the Treatment of Solid Tumors
Jul 18, 2023
Outsourcing-Pharma
KSQ: Roche licenses drug to target cancer DNA damage response
Jul 13, 2023
Contract Pharma
KSQ: KSQ Therapeutics, Roche Enter Worldwide KSQ-4279 License Agreement
Jul 13, 2023
Endpoints News
KSQ: Roche licenses KSQ's PhI cancer small molecule, with cash infusion to help bankroll biotech's TIL cell therapies
May 19, 2023
Biospectrum Asia
KSQ: US-based startup KSQ inks immuno-oncology deal worth $510 M with Japan's Takeda Pharma
KSQ Competitors
1
2
3
4
5
6
7
8
9
10